Christopher J. McDonald
Christopher J. McDonald works with both the Firm's Antitrust & Competition Litigation Practice and its Securities Litigation Practice.
In the antitrust field, Chris is currently litigating In re Generic Pharmaceuticals Pricing Antitrust Litigation, in which the Firm has been appointed to the End-Payor Plaintiffs Steering Committee, In re Treasury Securities Auction Antitrust Litigation, in which the Firm serves as interim co-lead counsel, and In re Platinum and Palladium Antitrust Litigation, in which the Firm serves as co-lead counsel. Chris was also co-lead counsel in In re TriCor Indirect Purchaser Antitrust Litigation, obtaining a $65.7 million settlement on behalf of the plaintiff class. He has been recommended in Antitrust Litigation Class Action by The Legal 500.
Chris' securities practice has developed a focus on life sciences industries; his cases often involve claims against pharmaceutical, biotechnology, or medical device companies. Most recently, Chris served as lead counsel in In re Amgen Inc. Securities Litigation, a case against global biotechnology company Amgen and certain of its former executives, resulting in a $95 million settlement. He also served as co-lead counsel in In re Schering-Plough Corporation / ENHANCE Securities Litigation, which resulted in a $473 million settlement, one of the largest securities class action settlements ever against a pharmaceutical company and among the largest recoveries ever in a securities class action that did not involve a financial restatement. He was also an integral part of the team that successfully litigated In re Bristol-Myers Squibb Securities Litigation, where Labaton Sucharow secured a $185 million settlement, as well as significant corporate governance reforms, on behalf of Bristol-Myers Squibb shareholders.
Chris began his legal career at Patterson, Belknap, Webb & Tyler LLP, where he gained extensive trial experience in areas ranging from employment contract disputes to false advertising claims. Later, as a senior attorney with a telecommunications company, Chris advocated before regulatory agencies on a variety of complex legal, economic, and public policy issues.
During his time at Fordham University School of Law, Chris was a member of the Law Review. He is currently a member of the New York State Bar Association, its Antitrust Law Section, and the Section’s Cartel and Criminal Practice Committee. He is also a member of the New York City Bar Association.
Fordham University School of Law
B.A., cum laude, 1985
Settled | Resolved Cases
- In re Amgen Inc. Securities Litigation
- In re Beckman Coulter, Inc. Securities Litigation
- In re Bristol-Myers Squibb Securities Litigation
- In re Schering-Plough Corporation / ENHANCE Securities Litigation
- In re Stock Exchange Options Trading Antitrust Litigation
- In re TriCor Indirect Purchaser Antitrust Litigation
1993, New York
2012, U.S. Supreme Court
U.S. Court of Appeals
2006, Second Circuit
2005, Third Circuit
2017, Fourth Circuit
2009, Ninth Circuit
2007, Federal Circuit
U.S. District Court
1994, Southern District of New York
1994, Eastern District of New York
1998, Western District of Michigan
In the News
- Press Release, Labaton Sucharow Recovers $95 Million in Securities Class Action Against Biotech Titan Amgen Inc. (07/20/2016)
- Law360, VIDEO: A Primer on Halliburton v. Erica P. John Fund (05/23/2014)
- Forbes, Supreme Court May Hem In, But Not Overrule Securities Class-Action Theory (03/05/2014)
- Law360, Top Plaintiffs Firms Say Amgen No License To Print Money (02/28/2013)
- Pensions & Investments, Supreme Court Rules on Class Action, Gabelli Cases (02/27/2013)
- Pink Sheet DAILY, Securities Fraud Class Action Suits Could Grow After Amgen's Supreme Court Loss (02/27/2013)
- The New York Times, Merck Settles Suits Over Cholesterol Drug (02/14/2013)
- Reuters, Merck to Pay $688 Million to Settle Enhance Lawsuits (02/14/2013)